Search

EHA Statement on the Erasmus MC Attack

Sep 29 2023

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Myelodysplastic Syndromes (MDS)

The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

EHA and EMBL-EBI are launching CBTH

Jun 02 2022 Posted in Press releases

The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.